Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province)

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2013 Mar 16

PMID 23492839

Citations 4

Authors

Azadeh Lohrasbi Nejad

Mohammad Mehdi Yaghoobi

Affiliations

Soon will be listed here.

Abstract

Objectives: P53 is an important tumor suppressor, which is mutated in later stages of many cancers and leads to resistance to chemotherapy. The aim of this study was to reveal mutations of TP53 in colorectal cancer in Kerman province.

Materials And Methods: A total of Forty-three colon cancer specimens as paraffin block or fresh tissues, which passed stage IIIA, were selected. Three exons 5, 7 and 8 of P53 were amplified by PCR technique and sequenced directly.

Results: The results showed two deletions at codon 140 and 142 in one tumor sample. GAT→AAT mutation at codon 184, and CGG→TGG mutation at codon 248 were seen in some tumor samples. Some mutations were also observed in middle of intron 7 in some tumor or normal tissues.

Conclusion: Some of those patients with mutation in P53 gene had metastasis in other organs. Therefore, genetic test before chemotherapy is helpful for successful treatment.

Citing Articles

Association of MTHFR C677T variant genotype with serum folate and Vit B12 in Iranian patients with colorectal cancer or adenomatous polyps.

Ghorbani M, Azghandi M, Khayami R, Baharara J, Kerachian M BMC Med Genomics. 2021; 14(1):246.

PMID: 34645434 PMC: 8513199. DOI: 10.1186/s12920-021-01097-5.

PKM2 in carcinogenesis and oncotherapy.

He X, Du S, Lei T, Li X, Liu Y, Wang H Oncotarget. 2018; 8(66):110656-110670.

PMID: 29299177 PMC: 5746412. DOI: 10.18632/oncotarget.22529.

Rising rates of colorectal cancer among younger Iranians: is diet to blame?.

Hessami Arani S, Kerachian M Curr Oncol. 2017; 24(2):e131-e137.

PMID: 28490936 PMC: 5407876. DOI: 10.3747/co.23.3226.

Colorectal cancer in iran: molecular epidemiology and screening strategies.

Dolatkhah R, Somi M, Bonyadi M, Asvadi Kermani I, Farassati F, Dastgiri S J Cancer Epidemiol. 2015; 2015:643020.

PMID: 25685149 PMC: 4312646. DOI: 10.1155/2015/643020.

References

Ambs S, BENNETT W, Merriam W, Ogunfusika M, Oser S, Harrington A . Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999; 91(1):86-8. DOI: 10.1093/jnci/91.1.86. View

Compton C, Greene F . The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308. DOI: 10.3322/canjclin.54.6.295. View

Benhattar J, Cerottini J, Saraga E, Metthez G, Givel J . p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer. 1996; 69(3):190-2. DOI: 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V. View

Vousden K, Lane D . p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-83. DOI: 10.1038/nrm2147. View

Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B . Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008; 653(1-2):6-13. DOI: 10.1016/j.mrgentox.2008.01.012. View

Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo A, Monti F . Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005; 204(2):484-8. DOI: 10.1002/jcp.20310. View

Parkin D, Pisani P, Ferlay J . Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80(6):827-41. DOI: 10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p. View

Lyall M, Dundas S, Curran S, Murray G . Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006; 12(4):1184-91. DOI: 10.1158/1078-0432.CCR-05-1864. View

Alsner J, Yilmaz M, Guldberg P, Hansen L, Overgaard J . Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res. 2000; 6(10):3923-31. PMC: 3300808. DOI: 10.1186/bcr109. View

10.

Yu J, Rak J, Coomber B, Hicklin D, Kerbel R . Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295(5559):1526-8. DOI: 10.1126/science.1068327. View

11.

Boyle P, Langman J . ABC of colorectal cancer: Epidemiology. BMJ. 2000; 321(7264):805-8. PMC: 1118620. DOI: 10.1136/bmj.321.7264.805. View

12.

Coombs N, Gough A, Primrose J . Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res. 1999; 27(16):e12. PMC: 148555. DOI: 10.1093/nar/27.16.e12. View

13.

Boyer J, McLean E, Aroori S, Wilson P, McCulla A, Carey P . Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004; 10(6):2158-67. DOI: 10.1158/1078-0432.ccr-03-0362. View

14.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T . Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol. 2006; 17(5):842-7. DOI: 10.1093/annonc/mdl035. View

15.

Weekes J, Lam A, Sebesan S, Ho Y . Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol. 2009; 15(29):3597-602. PMC: 2721232. DOI: 10.3748/wjg.15.3597. View

16.

Baumbusch L, Myhre S, Langerod A, Bergamaschi A, Geisler S, Lonning P . Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer. 2006; 5:47. PMC: 1636663. DOI: 10.1186/1476-4598-5-47. View

17.

Angelopoulou K, Levesque M, Katsaros D, Shipman R, Diamandis E . Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem. 1998; 44(1):72-7. View

18.

Munro A, Lain S, Lane D . P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92(3):434-44. PMC: 2362083. DOI: 10.1038/sj.bjc.6602358. View

19.

Lam A, Ong K, Ho Y . hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorectal Dis. 2008; 23(6):587-94. DOI: 10.1007/s00384-008-0455-7. View

20.

Xinarianos G, Liloglou T, Prime W, Sourvinos G, Karachristos A, Gosney J . p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int J Cancer. 2002; 101(3):248-52. DOI: 10.1002/ijc.10598. View